Mery-Mignard D - Search Results

1

A phase II study of irinotecan in patients with advanced renal cell carcinoma.

Fizazi K, Rolland F, Chevreau C, Droz JP, Mery-Mignard D, Culine S, Escudier B. Fizazi K, et al. Cancer. 2003 Jul 1;98(1):61-5. doi: 10.1002/cncr.11474. Cancer. 2003. PMID: 12833456 Free article. Clinical Trial.

2

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z, Bugat R. Delord JP, et al. Among authors: mery mignard d. Br J Cancer. 2005 Mar 14;92(5):820-6. doi: 10.1038/sj.bjc.6602354. Br J Cancer. 2005. PMID: 15756252 Free PMC article. Clinical Trial.

3

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.

Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, Tolcher AW. Soria JC, et al. Among authors: mery mignard d. Eur J Cancer. 2013 May;49(8):1799-807. doi: 10.1016/j.ejca.2013.01.003. Epub 2013 Feb 26. Eur J Cancer. 2013. PMID: 23485230 Clinical Trial.

4

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E. Wasserman E, et al. J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751. J Clin Oncol. 1999. PMID: 10561212 Clinical Trial.

5

Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.

Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Méry-Mignard D, Rougier P. Ducreux M, et al. J Clin Oncol. 1999 Sep;17(9):2901-8. doi: 10.1200/JCO.1999.17.9.2901. J Clin Oncol. 1999. PMID: 10561369

6

A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

Louvet C, André T, Gamelin E, Garcia ML, Saavedra A, Lenaers G, de Gramont A, Méry-Mignard D, Kalla S. Louvet C, et al. Among authors: mery mignard d. Bull Cancer. 2004 Dec;91(12):279-84. Bull Cancer. 2004. PMID: 15634630 Free article. Clinical Trial.

7

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, Kramar A. Ychou M, et al. Ann Oncol. 2003 Mar;14(3):481-9. doi: 10.1093/annonc/mdg119. Ann Oncol. 2003. PMID: 12598357 Free article. Clinical Trial.

8

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

Mitry E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P. Mitry E, et al. Among authors: mery mignard d. Ann Oncol. 2004 Jul;15(7):1013-7. doi: 10.1093/annonc/mdh267. Ann Oncol. 2004. PMID: 15205193 Free article.

9

Circadian rhythm of irinotecan tolerability in mice.

Filipski E, Lemaigre G, Liu XH, Méry-Mignard D, Mahjoubi M, Lévi F. Filipski E, et al. Among authors: mery mignard d. Chronobiol Int. 2004 Jul;21(4-5):613-30. doi: 10.1081/cbi-120040183. Chronobiol Int. 2004. PMID: 15470958

10

Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.

Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, Hua A, Méry-Mignard D. Rougier P, et al. Ann Oncol. 2002 Oct;13(10):1558-67. doi: 10.1093/annonc/mdf259. Ann Oncol. 2002. PMID: 12377643 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page